|
Shire Pharmaceuticals is to acquire Transkaryotic Therapies, the US biotechnology company that produces drugs for genetic disorders, for £839m. 25-Apr-2005 Shire Pharmaceuticals is to sell its vaccines division to ID Biomedical of Canada for £66m, and Shire will loan about £60m to ID to fund the development of new products. 21-Apr-2004 Shire Pharmaceuticals is looking to spend up to £550m on a large acquisition, as part of a strategy to reduce its reliance on its hyperactivity drug. 12-Mar-2004 Shire Pharmaceuticals is considering plans to close its early-stage drugs research unit, sell off its vaccines business and seek large acquisitions in the US. 01-Aug-2003 Shire Pharmaceuticals has awarded a $18m contract to AMEC to build a global vaccines research centre at its site in Laval, Canada. 17-Apr-2003 Shire Pharmaceuticals has raised £45m from the sale of its four remaining over-the-counter products to Purdue Pharma. 31-Dec-2002 Shire Pharmaceuticals is to acquire Atlantic Pharmaceutical Services, the US-based pharmaceuticals manufacturer with 100 staff in Maryland, from Niro for £11m. 16-Sep-2002 Skyepharma has raised £15m from the sale of the European distribution rights of the Solaraze skin treatment to Shire Pharmaceuticals, and has also announced a £25m investment from Kowa of Japan. 14-May-2002 Shire Pharmaceuticals has raised £280m from an issue of convertible bonds, in order to fund the acquisition of speciality pharmaceutical products and support its expansion into Japan and Europe. 16-Aug-2001 Shire is planning to cut research costs and make annual savings of £22m following the acquisition of BioChem of Canada, and has also announced an intention to move into the Japanese pharmaceuticals market. 26-Jan-2001 Shire Pharmaceuticals is to acquire BioChem Pharma of Canada for £2.7bn, in order to broaden its portfolio of speciality pharmaceutical products. 12-Dec-2000 Shire has opened an operating subsidiary in Spain, as part of a strategy to develop a global pharmaceuticals business. 08-Jun-2000 Shire Pharmaceuticals is acquiring the French, Italian and German subsidiaries of Fuisz Technologies of the US for £24m, as part of a strategy to build up a global drug development business. 25-Oct-1999 Shire Pharmaceuticals is planning to make a significant acquisition in continental Europe by the end of next year. 20-Oct-1999 Shire Pharmaceuticals is to acquire Roberts Pharmaceutical of the US for £570m, and is now looking at ways to increase sales in continental Europe. 27-Jul-1999 Shire Pharmaceuticals is said to have been negotiating a merger with Medeva, but talks have stalled due to a disagreement over price. 15-Jul-1999 Shire Pharmaceuticals is considering plans to spend up to £800m on a major acquisition in Europe. 12-May-1999 Production of Shire Pharmaceuticals' Arenol hyperactivity drug could be halted for up to 10 months following an explosion at a US factory. 07-Aug-1998 Shire Pharmaceuticals has announced encouraging early results from trials of its galantamine treatment for Alzheimer's disease, indicating that it helps to slow memory loss. 20-Jul-1998 Shire Pharmaceuticals is to re-acquire the worldwide rights to Carbatol, the anticonvulsant, from Elan Corp for £15m. 27-Dec-1997 Shire Pharmaceuticals has announced "excellent" initial trial results for Galantamine, a new drug for Alzheimer's disease. 16-Sep-1997 Shire Pharmaceuticals is acquiring Richwood Pharmaceuticals of Kentucky, the maker of treatments for disorders of the central nervous system, for up to £113m. 05-Aug-1997 Shire Pharmaceuticals is to start trials on Galanthamine as a treatment for Chronic Fatigue Syndrome. 07-May-1997 Shire Pharmaceuticals is acquiring Pharmavene, the US drugs delivery concern, for up to £104m, and will make further acquisitions using funding from a £11.5m planned share offer. 26-Feb-1997 Shire Pharmaceuticals' Alzheimer's disease drug, Reminyl, is moving into the final stage of clinical trials in the US, through its partner Janssen Pharmaceutica. 22-Oct-1996 Shire Pharmaceuticals, the developer of prescription medicines, is in discussions to acquire two or three companies that could market its products. 28-Sep-1996 Shire Pharmaceuticals Group expects to raise £35m from a flotation and will use £20m on development. 26-Jan-1996 Shire Pharmaceuticals Group is to develop and market galanthamine, the Alzheimer's treatment, in a deal with Johnson & Johnson's Belgian operation, Janssen Pharmaceutics. 25-Jan-1996 Shire Pharmaceuticals Group plans to raise about £25m through a flotation. 14-Dec-1995
|